BILLERICA, Mass., July 13, 2016 /PRNewswire/ -- ProterixBio, Inc. today announced that the company has appointed Fernando Martinez, M.D. to its scientific and medical advisory board. Dr. Martinez is a global clinical expert in pulmonary diseases such as chronic obstructive pulmonary disease (COPD) and idiopathic pulmonary fibrosis (IPF). This appointment reflects ProterixBio's strategic focus on developing novel solutions to improve the effectiveness and efficiency of care for major pulmonary disorders. Dr. Martinez will assist the company with strategic advice related to its clinical research studies as well as the development of future healthcare solutions.
ProterixBio is developing innovative products to transform the management of chronic pulmonary diseases, with the initial applications focusing on COPD, IPF and cystic fibrosis (CF). COPD (which affects over 12+ million people in the US alone) impacts the productivity and quality of life of millions of individuals and represents a significant portion of global health care spending. ProterixBio has recently appointed a number of leading research and clinical experts to serve as scientific and medical advisors to help the company with research and development initiatives in this space.
"ProterixBio is thrilled to have Dr. Martinez join our scientific and medical advisory board," said Grace E. Colón, Ph.D., President and Chief Executive Officer of ProterixBio. "His decades of leadership in the field and passion for our vision and mission will help us at a critical time as we soon reach feasibility stage for our first product for COPD disease management. He is a wonderful addition to our team of advisors, and my colleagues and I look forward to working with him in future."
"I am honored and excited to advise ProterixBio on critical diseases such as COPD and idiopathic pulmonary fibrosis," said Dr. Fernando Martinez, Executive Vice Chair of Weill Cornell Medical College. "I look forward to collaborating with the company on clinical studies designed to better assess their disease. A better evaluation of patients via molecular and traditional methods will ultimately benefit pulmonary patients through better management of their disease, fostering personalized care and, hopefully, improving outcomes and relieving burden on our patients."
Dr. Martinez is the executive Vice Chair of Medicine at Weill Cornell Medical College. He has been listed in "Best Doctors of America" every year since 2002. Dr. Martinez is a premiere translational researcher in chronic lung disease, and is nationally and internationally recognized for his grant-funded seminal studies in the phenotypic and functional classification, and clinical interventions in COPD and interstitial lung disease. He has authored 326 peer-reviewed manuscripts, 36 review articles in addition to 32 book chapters, and has mentored numerous trainees, with many of his mentees establishing successful independent research programs.
Dr. Martinez received both his BSc and M.D. at the University of Florida, and completed his Internal Medicine residency at Beth Israel Hospital/Harvard Medical School in 1986. He then held a Pulmonary and Critical Care Medicine Fellowship at Boston University prior to joining University of Michigan Medical Center as Assistant Professor of Medicine in 1991, where he rose to the rank of Professor of Medicine in 2002 and served in a number of medical leadership positions. He received a MS in Biostatistics and Clinical Study Design Biostatistics and Clinical Study Design from the University of Michigan, School of Public Health in 2001. He was appointed to his current position in 2014.
ProterixBio develops and commercializes disease management solutions that integrate novel bioclinical analytics with digital tools to improve the effectiveness and efficiency of chronic disease care. The company is dedicated to leveraging its innovative approach and differentiated expertise to build transformative disease management platforms. ProterixBio's initial focus is on pulmonary diseases such as COPD (chronic obstructive pulmonary disease), which affects more than 12 million Americans. While ProterixBio is currently focused primarily on pulmonary diseases, the company's unique platform and expertise are easily applied to other diseases areas. In particular, other diagnostic opportunities are currently being explored in neurodegenerative and oncologic diseases. ProterixBio is headquartered in Billerica, Mass.
Cook Williams Communications, Inc.